Feb 3 (Reuters) - United Therapeutics Corp UTHR.O:
UNITED THERAPEUTICS CORPORATION ANNOUNCES FDA CLEARANCE OF ITS INVESTIGATIONAL NEW DRUG APPLICATION FOR THE UKIDNEY XENOTRANSPLANTATION CLINICAL TRIAL
UNITED THERAPEUTICS CORP - FIRST XENOTRANSPLANT EXPECTED AROUND MID-YEAR 2025
Source text: ID:nBw73NtjRa
Further company coverage: UTHR.O
((Reuters.Briefs@thomsonreuters.com;))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.